Evaluation of cardiac function in patients with thalassemia major.
A W Nienhuis, P Griffith, H Strawczynski...
https://pubmed.ncbi.nlm.nih.gov/6930878Completed
Phase 2
Age: 5Years +
All Genders
ID00000595
Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2013-11-26
N/A
Participants Needed
N/A
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine whether deferoxamine prevented the complications of transfusional iron overload.
CONDITIONS
Official Title
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
Who Can Participate
Age: 5Years +
All Genders
Eligibility Criteria
You may qualify if you...
Males and females, 5 years or older, with transfusional hemochromatosis.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Site Locations not provided
Location information for this trial is currently unavailable.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.
G M Brittenham, P M Griffith, A W Nienhuis...
https://pubmed.ncbi.nlm.nih.gov/8047080